- Home
- WRBY vs SUPN Comparison
WRBY vs SUPN Comparison
Compare WRBY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WRBY | SUPN |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.9B |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WRBY | SUPN |
|---|---|---|
| Price | $22.60 | $49.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 5 |
| Target Price | $25.43 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 6.1M | 602.1K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $850,580,000.00 | $681,539,000.00 |
| Revenue This Year | $15.47 | $8.32 |
| Revenue Next Year | $13.06 | $23.36 |
| P/E Ratio | $3,854.07 | ★ N/A |
| Revenue Growth | ★ 14.55 | 4.54 |
| 52 Week Low | $13.63 | $29.16 |
| 52 Week High | $31.00 | $57.65 |
Technical Indicators
Market Signals| Indicator | WRBY | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 52.86 |
| Support Level | $21.46 | $51.01 |
| Resistance Level | $27.29 | $52.30 |
| Average True Range (ATR) | 1.42 | 1.38 |
| MACD | -0.66 | 0.05 |
| Stochastic Oscillator | 13.90 | 49.85 |
Price Performance
Historical ComparisonAbout WRBY Warby Parker Inc.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.